A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This study is a randomized, controlled, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of SHR-A2009 combined with aumolertinib versus aumolertinib monotherapy in treatment-naïve subjects with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer.
Epistemonikos ID: 44eff13029791714031c1ac6cb13277cdfbb2c38
First added on: Sep 20, 2025